1 year return (CAGR)
-31.25%
Kuros Biosciences AG Exchange (SW, CHF)
KURN.SW
19.07
+0.66 (+3.59%)
HealthcareMedical Devices
Loading...
3 year return (CAGR)
108.63%
5 year return (CAGR)
50.50%
10 year return (CAGR)
2.23%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
756.57M
Price/Sales
3.08
Ent value
796.86M
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
738.64
PEG
-
Forward P/E
33.51
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 18.40 |
| Daily high | 19.07 |
| Daily low | 18.10 |
| Daily Volume | 255K |
| All-time high | 11956.37 |
| 1y analyst estimate | 34.29 |
| Beta | 0.76 |
| EPS (TTM) | 0.03 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 10 Mar 2026 |
Downside potential
Loading...
Downside potential data
| KURN.SW | S&P500 | |
| Current price drop from All-time high | -99.84% | -1.06% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 26 Apr 2023 | 9 Mar 2009 |
| Avg drop from high | -81.53% | -10.67% |
| Avg time to new high | 109 days | 12 days |
| Max time to new high | 4875 days | 1805 days |
News
Ad-hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerlan...
August 13, 2026
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Schlieren (Zürich), Switzerland, June 17, 2026 – Kuros Biosciences (“K...
June 17, 2026
As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical tensions, investors are keenly observing growth companies that demonstrate resilience. In such a...
June 12, 2026
As European markets navigate a period of uncertainty marked by geopolitical tensions and economic contractions, investors are increasingly focusing on companies that demonstrate resilience and potenti...
June 12, 2026
As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical developments, investors are increasingly focusing on companies with strong growth potential and ...
June 10, 2026
As European markets navigate a period of uncertainty marked by mixed economic signals and geopolitical tensions, investors are increasingly focused on identifying resilient growth opportunities. In th...
June 8, 2026
As European markets navigate the complexities of geopolitical developments and economic adjustments, indices like Germany's DAX and France's CAC 40 have shown resilience with notable gains. In this en...
June 5, 2026
As European markets navigate the complexities of geopolitical developments and economic shifts, such as the ongoing U.S.-Iran negotiations and supply chain challenges, investors are increasingly focus...
June 4, 2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product ...
April 14, 2026
Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone hea...
April 15, 2026